June 25, 2025 4:36pm

As I wrote this a.m., “Declare a cease fire for the portfolio, don’t be distracted by uncle algo and his electronic trading dwarfs trying to leak the upside”

News: Ionis Pharmaceuticals (IONS +$0.36 or +0.91% to $40.00) its partner, Biogen (BIIB), shared positive topline results from the P1 study of salanersen (ION306/BIIB115), an investigational antisense oligonucleotide (ASO) being developed for the potential treatment of spinal muscular atrophy (SMA). Exploratory clinical outcome data show clinically meaningful improvements in function and attainment of new World Health Organization (WHO) milestones over one year.

When you want to decant or fill your portfolio carafe, always consider it, a glass half-full

Never leave an investor uninformed!  

On point, short on words, long on facts and being judicious!

My mission is to provide clear, actionable guidance on a regular basis to help investors and traders navigate the uncertain and often irrational financial markets.

I put hours of effort to create reporting, while leveraging my 40 years of operating. investigative and research experiences to analyze the key market-moving events and distill that into a cogent outlook.

 

Wednesday’s RegMed Investors’ (RMi) pre-open: Too hot to handle … https://www.regmedinvestors.com/articles/13973

Tuesday night’s RegMed Investors (RMi) Closing Bell: clicking on the after burners … https://www.regmedinvestors.com/articles/13972

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN): PONZI Scheme at its best or was convicted Bernie Madoff also resurrected … https://www.regmedinvestors.com/articles/13812

 

Wednesday: The Dow closed DOWN -160.59 points or -0.25%, the S&P closed DOWN -0.02 points or -0.00% while the Nasdaq closed UP +61.02 points or +0.31%

  • Theme of the session, tailwinds about to close all-time highs

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies

  • New home sales, which came in at the slowest pace since October 2024

Wednesday’s advance/decline line opened negative with 4 incliners, 27 decliners and 4 flats ending with a negative close of 14 incliners, 17 decliners and 4 flats      

Metrics:  Wednesday, the IBB was down -0.72%, the XBI was down -0.55% while the VIX was down -0.71 points or -4.06% at 16.77

 

Q2/25 – June – 1 market holiday, 1 neutral, 7 negative and 10 positive closes

  • May – 1 market holiday, 10 negative and 11 positive closes
  • April – 11 positive and 10 negative closes

 

Wednesday Closing UP (10 of 14) +$ after Tuesday’s

  • CRISPR Therapeutics (CRSP +$0.88 after Tuesday’s +$1.23 after Monday’s +$1.30),
  • Ionis Pharmaceuticals (IONS +$0.36 after Tuesday’s +$1.97 after Monday’s +$0.26),
  • Ultragenyx Pharmaceuticals (RARE +$0.27),
  • AxoGen (AXGN +$0.11 after Tuesday’s +$0.36 after Monday’s +$0.06)
  • uniQure NV (QURE +$0.11),
  • Mesoblast (MESO +$0.10),
  • Compass Therapeutics (CMPX +$0.07),
  • Sangamo Therapeutics (SGMO +$0.0682),
  • Moderna (MRNA +$0.06 after Tuesday’s +$1.13 after Monday’s -$0.26),
  • Adverum Biotechnologies (ADVM +$0.04)

Flat (4)

  • bluebird bio (BLUE) P/E acquired
  • Harvard Apparatus RT (OTCQB: HRGN)
  • Homology Medicine (FIXX)
  • MiMedx (MDXG)

Wednesday’s Closing DOWN (10 of 17): -$ after Tuesday’s

  • Alnylam Pharmaceuticals (ALNY -$3.06 after Tuesday’s +$11.87 after Monday’s +$3.43),
  • Vericel (VCEL -$1.46 after Tuesday’s +$1.54 after Monday’s -$0.22),
  • BioLife Solutions (BLFS -$0.43 after Tuesday’s +$0.44 after Monday’s +$0.14),
  • Beam Therapeutics (BEAM -$0.39 after Tuesday’s +$0.44 after Monday’s -$0.05),
  • Lenz Therapeutics (LENZ -$0.26 after Tuesday’s -$0.77 after Monday’s +$0.54),
  • Solid Biosciences (SLDB -$0.115 after Tuesday’s +$0.34 after Monday’s -$0.28),
  • Precigen (PGEN -$0.08),
  • Agenus (AGEN -$0.07)
  • Editas Medicine (EDIT -$0.06),
  • Voyager Therapeutics (VYGR -$0.06),

 

The BOTTOM LINE: The cell and gene therapy sector intercepted a few algo and electronic trading missiles with a barely negative exclamation close…

A new week <6/23 to 6/27> opens with a barely Monday negative close followed by a Tuesday positive close and a barely negative close on Wednesday …

This week, 6/16 – 6/20 started with a Monday positive close … followed by Tuesday’s negative close … and a Wednesday’s positive close, Thursday’s market holiday and Friday’s negative close.

  • The week of 6/9 – 6/13; Friday, the cell and gene therapy sector stayed in negative territory following Thursday's trading session ended with a negative territory, after May's Producer Price Index (PPI) report following Wednesday's negative close after May's Consumer Price Index (CPI) report post Monday’s neutral close.
  • The cell and gene therapy sector popped Friday after Thursday’s reverses on Thursday from a negative open with a barely positive close after Wednesday’s positive close – although slipping
  • Following upsides on Tuesday and Monday) after its “napping and waking” in the May share pricing doldrums initiated by a sweetener of BPMC getting an acquired by BMY, MRNA regulatory approval and BNTX’s partnership with BMY.

As I also wrote, about June… Some believe in a “June Swoon;” however, June will be no better or worse than any other month. Although, I consider the so-called summer rally after the peripatetic or wandering.”

  • Although historically, June (in the past) has been a slow or weak month – I/we just saw a tremendous start (6/2) with partnership, acquisition and regulatory news 
  • Also, ASCO opens this month with probably a lot of news flow attracting attention of funds such as hedges and electronic traders.

There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

 

June ‘25: understand the “flow” …

This week ...

  • 6/25 - Wednesday closed negative with 14 positive, 17 negative and 4 flats
  • 6/24 - Tuesday closed positive with 30 positive, 3 negative and 2 flats
  • 6/23 - Monday closed negative with 15 positive, 16 negative and 4 flats

Last week ...

  • 6/20 - Friday closed negative with 14 positive, 18 negative and 3 flats
  • 6/19 – Thursday was a market holiday
  • 6/18 – Wednesday closed positive with 21 positive, 11 negative and 3 flats
  • 6/17 - Tuesday closed negative with 10 positive, 23 negative and 2 flats
  • 6/16 - Monday closed positive with 20 positive, 11 negative and 4 flats

 

“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Wednesday: CRISPR Therapeutics (CRSP), Ionis Pharmaceuticals (IONS) and Ultragenyx Pharmaceuticals (RARE)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS) and Vericel (VCEL)
  • Monday: Alnylam Pharmaceuticals (ALNY), Lenz Therapeutics (LENZ) and CRISPR Therapeutics (CRSP)
  • Friday: Moderna (MRNA), AxoGen (AXGN) and

The worst three (3) in the session: 

  • Wednesday: Alnylam Pharmaceuticals (ALNY), Vericel (VCEL) and BioLife Solutions (BLFS)
  • Tuesday: Lenz Therapeutics (LENZ), Blueprint Medicine (BPMC) and Sage Therapeutics (SAGE)
  • Monday: Vericel (VCEL), Regenxbio (RGNX) and Ultragenyx Pharmaceuticals (RARE)
  • Friday: Mesoblast (MESO), uniQure NV (QURE) and Alnylam Pharmaceuticals (ALNY)

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.